Display options
Cite
Wu D, Lee D, Sung YK. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respir Res. 2011;12:45doi: 10.1186/1465-9921-12-45.
Wu, D., Lee, D., & Sung, Y. K. (2011). Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respiratory research, 1245. https://doi.org/10.1186/1465-9921-12-45
Wu, Dongmei, et al. "Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review." Respiratory research vol. 12 (2011): 45. doi: https://doi.org/10.1186/1465-9921-12-45
Wu D, Lee D, Sung YK. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respir Res. 2011 Apr 11;12:45. doi: 10.1186/1465-9921-12-45. PMID: 21477377; PMCID: PMC3090995.
Copy Download .nbib Format: NLM
Share it on

Respir Res. 2011 Apr 11;12:45. doi: 10.1186/1465-9921-12-45.

Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.

Respiratory research

Dongmei Wu, Dongwon Lee, Yong Kiel Sung

Affiliations

  1. Department of Research, Mount Sinai Medical Center, Miami Beach, FL 33140, USA. [email protected]

PMID: 21477377 PMCID: PMC3090995 DOI: 10.1186/1465-9921-12-45

Abstract

There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathological features, including inflammation, smooth muscle contraction and remodeling. No existing drug provides the combined potential advantages of reducing vascular- and bronchial-constriction, and anti-inflammation. Vasoactive intestinal peptide (VIP) is widely expressed throughout the cardiopulmonary system and exerts a variety of biological actions, including potent vascular and airway dilatory actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of airway secretions. VIP has emerged as a promising drug candidate for the treatment of cardiopulmonary disorders such as PAH, asthma, and COPD. Clinical application of VIP has been limited in the past for a number of reasons, including its short plasma half-life and difficulty in administration routes. The development of long-acting VIP analogues, in combination with appropriate drug delivery systems, may provide clinically useful agents for the treatment of PAH, asthma, and COPD. This article reviews the physiological significance of VIP in cardiopulmonary system and the therapeutic potential of VIP-based agents in the treatment of pulmonary diseases.

References

  1. Am Heart J. 1996 Jul;132(1 Pt 1):187-9 - PubMed
  2. Peptides. 2011 Feb;32(2):401-7 - PubMed
  3. Cell Tissue Res. 1981;220(2):231-8 - PubMed
  4. J Neuroimmunol. 1994 Jun;52(1):69-78 - PubMed
  5. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13854-9 - PubMed
  6. J Auton Nerv Syst. 1992 Sep;40(2):121-9 - PubMed
  7. Chest. 1975 Feb;67(2 Suppl):44S - PubMed
  8. Int J Cardiol. 1996 Oct 11;56(2):159-61 - PubMed
  9. Lancet. 2007 Sep 1;370(9589):765-73 - PubMed
  10. Am Rev Respir Dis. 1981 Nov;124(5):531-6 - PubMed
  11. Ann Anat. 2003 Apr;185(2):153-61 - PubMed
  12. Eur J Hum Genet. 2007 Jan;15(1):18-22 - PubMed
  13. J Lab Clin Med. 1980 Oct;96(4):666-72 - PubMed
  14. Eur Respir J. 2010 Apr;35(4):730-4 - PubMed
  15. Am J Physiol. 1990 Aug;259(2 Pt 1):L151-5 - PubMed
  16. J Comp Neurol. 1998 May 11;394(3):326-34 - PubMed
  17. Am J Cardiol. 1987 Dec 1;60(16):1356-61 - PubMed
  18. Neurochem Res. 1997 Aug;22(8):1013-21 - PubMed
  19. Am J Physiol. 1992 Oct;263(4 Pt 2):H1300-5 - PubMed
  20. Cell Tissue Res. 1989 Nov;258(2):259-67 - PubMed
  21. Mol Pharmacol. 1988 Oct;34(4):506-17 - PubMed
  22. Circulation. 2007 Mar 13;115(10):1260-8 - PubMed
  23. Peptides. 2007 Sep;28(9):1640-50 - PubMed
  24. Biochem Biophys Res Commun. 1989 Feb 15;158(3):850-4 - PubMed
  25. Timely Top Med Cardiovasc Dis. 2005 Oct 03;9:E33 - PubMed
  26. J Pharmacol Exp Ther. 1986 Oct;239(1):249-55 - PubMed
  27. Physiology (Bethesda). 2005 Feb;20:28-35 - PubMed
  28. J Immunol. 2004 Sep 15;173(6):4154-63 - PubMed
  29. Regul Pept. 2004 Feb 15;117(2):149-54 - PubMed
  30. Expert Rev Cardiovasc Ther. 2005 Jul;3(4):565-9 - PubMed
  31. Eur J Pharm Sci. 2010 Nov 20;41(3-4):508-14 - PubMed
  32. J Immunol. 1999 Sep 15;163(6):3071-5 - PubMed
  33. J Leukoc Biol. 1998 Dec;64(6):828-34 - PubMed
  34. Ann N Y Acad Sci. 1996 Dec 26;805:717-22 - PubMed
  35. Jpn J Physiol. 1998 Oct;48(5):301-31 - PubMed
  36. Trans Assoc Am Physicians. 1984;97:304-10 - PubMed
  37. Acta Physiol Scand. 1981 Aug;112(4):427-36 - PubMed
  38. Br J Pharmacol. 1987 May;91(1):139-48 - PubMed
  39. Chest. 2003 Aug;124(2):474-81 - PubMed
  40. Clin Exp Immunol. 2009 Aug;157(2):225-34 - PubMed
  41. Endocrinology. 1982 Oct;111(4):1248-54 - PubMed
  42. J Clin Invest. 1994 Jun;93(6):2667-74 - PubMed
  43. Ann N Y Acad Sci. 2000;921:92-102 - PubMed
  44. Circulation. 2005 Feb 8;111(5):534-8 - PubMed
  45. Pharmacol Ther. 1989;41(3):515-34 - PubMed
  46. J Clin Invest. 1990 Sep;86(3):825-31 - PubMed
  47. Ann N Y Acad Sci. 2008 Nov;1144:148-53 - PubMed
  48. J Pharmacol Exp Ther. 1988 Jan;244(1):133-7 - PubMed
  49. J Appl Physiol (1985). 1986 Oct;61(4):1322-8 - PubMed
  50. Peptides. 1984 May-Jun;5(3):593-606 - PubMed
  51. Postgrad Med. 2005 Dec;118(6 Suppl Acute):2-8 - PubMed
  52. Cardiovasc Drugs Ther. 2006 Oct;20(5):377-86 - PubMed
  53. Pharmacol Rev. 1996 Mar;48(1):113-78 - PubMed
  54. J Appl Physiol (1985). 1988 Dec;65(6):2537-44 - PubMed
  55. Neuroimmunomodulation. 2002-2003;10(4):217-23 - PubMed
  56. Ann N Y Acad Sci. 2000;921:45-54 - PubMed
  57. Curr Drug Targets. 2011 Apr;12(4):501-13 - PubMed
  58. Science. 1970 Sep 18;169(3951):1217-8 - PubMed
  59. Annu Rev Physiol. 1997;59:89-144 - PubMed
  60. Histochemistry. 1985;82(4):313-9 - PubMed
  61. Nature. 1978 Oct 19;275(5681):661-2 - PubMed
  62. J Cardiovasc Pharmacol. 1990 Dec;16(6):1000-6 - PubMed
  63. Lab Invest. 2001 May;81(5):749-55 - PubMed
  64. Naunyn Schmiedebergs Arch Pharmacol. 2001 Oct;364(4):314-20 - PubMed
  65. J Am Coll Cardiol. 1986 Feb;7(2):406-13 - PubMed
  66. J Endocrinol Invest. 1986 Apr;9(2):191-200 - PubMed
  67. Eur Respir J. 2003 Aug;22(2):358-63 - PubMed
  68. Eur J Pharmacol. 1983 Mar 25;88(2-3):247-50 - PubMed
  69. Eur J Biochem. 2004 May;271(9):1757-67 - PubMed
  70. Cardiovasc Res. 2001 Jan;49(1):27-37 - PubMed
  71. Drug Des Discov. 1996 Apr;13(3-4):107-14 - PubMed
  72. J Immunol. 2003 Jan 1;170(1):308-14 - PubMed
  73. Peptides. 1984 Mar-Apr;5(2):143-50 - PubMed
  74. Regul Pept. 2002 Oct 15;108(2-3):165-73 - PubMed
  75. J Biol Chem. 1990 Sep 15;265(26):15371-4 - PubMed
  76. Eur J Pharmacol. 2006 Mar 8;533(1-3):182-94 - PubMed
  77. Gut. 1978 Nov;19(11):1049-53 - PubMed
  78. Immunology. 2008 Mar;123(3):398-410 - PubMed
  79. J Mol Med (Berl). 2002 Jan;80(1):16-24 - PubMed
  80. Trans Assoc Am Physicians. 1983;96:406-11 - PubMed
  81. J Immunol. 1989 May 15;142(10):3533-6 - PubMed
  82. Thorax. 2003 Mar;58(3):217-21 - PubMed
  83. Lancet. 1973 Jul 7;2(7819):14-6 - PubMed
  84. Am J Physiol. 1989 Oct;257(4 Pt 2):H1082-7 - PubMed
  85. J Immunol. 1999 Apr 15;162(8):4685-96 - PubMed
  86. Cardiovasc Surg. 2002 Apr;10(2):138-45 - PubMed
  87. Peptides. 2010 Jan;31(1):72-8 - PubMed
  88. J Clin Invest. 2003 May;111(9):1339-46 - PubMed
  89. Pulm Pharmacol Ther. 2001;14(5):391-401 - PubMed
  90. Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L880-6 - PubMed
  91. Trends Immunol. 2003 May;24(5):221-4 - PubMed
  92. Peptides. 2006 Dec;27(12):3107-14 - PubMed
  93. Am J Respir Crit Care Med. 1996 Jul;154(1):209-16 - PubMed
  94. Scand J Gastroenterol. 1978;13(7):807-13 - PubMed
  95. Cardiovasc Res. 1996 Nov;32(5):846-53 - PubMed
  96. Biochem Biophys Res Commun. 1987 Nov 13;148(3):1440-5 - PubMed
  97. Lancet. 1983 Nov 26;2(8361):1225-7 - PubMed
  98. Peptides. 1987 Jan-Feb;8(1):175-8 - PubMed
  99. Neuroscience. 1983 Jul;9(3):605-19 - PubMed
  100. Circ Res. 1990 Dec;67(6):1323-33 - PubMed

Substances

MeSH terms

Publication Types